Peptides for Endometriosis — Evidence-Based Overview

How peptide Targets Peptides for Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus — most commonly on the peritoneum, ovaries, and rectovaginal septum. The disease involves not just ectopic tissue growth but also a dysregulated immune environment, chronic pelvic inflammation, aberrant angiogenesis, neurogenic pain sensitization, and fibrosis. Current treatments focus on hormonal suppression and surgical excision, but many patients experience persistent symptoms or side effects from hormonal therapy. Peptides that target inflammation, immune modulation, and pain pathways represent an area of emerging interest, though clinical evidence specific to endometriosis is extremely limited for most peptide interventions.

BPC-157 (Body Protection Compound-157) is relevant to endometriosis primarily through its potent anti-inflammatory and cytoprotective properties. In preclinical models, BPC-157 modulates the nitric oxide system, reduces inflammatory cytokine production, and promotes tissue healing. Endometriosis lesions are driven by a pro-inflammatory peritoneal environment rich in TNF-alpha, IL-1beta, IL-6, and IL-8 — cytokines that BPC-157 has been shown to counteract in other inflammatory models. BPC-157 also modulates angiogenesis in a context-dependent manner, which is noteworthy because aberrant angiogenesis sustains endometriotic implants. However, the angiogenic effects of BPC-157 are complex and could theoretically either help or harm in the endometriosis context — this has not been studied. KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, has demonstrated anti-inflammatory effects through inhibition of NF-kappaB signaling and reduction of pro-inflammatory cytokine production. In inflammatory bowel disease models, KPV reduces mucosal inflammation and immune cell infiltration. These mechanisms are relevant to the peritoneal inflammation in endometriosis, though KPV has not been specifically studied in endometriosis models.

Vasoactive intestinal peptide (VIP) is an immunomodulatory neuropeptide that suppresses pro-inflammatory Th1 responses, promotes regulatory T cell differentiation, and inhibits macrophage activation. The immune dysregulation in endometriosis includes impaired NK cell cytotoxicity, elevated peritoneal macrophage activation, and a shift toward inflammatory cytokine profiles — all processes that VIP modulates in preclinical models. VIP also has analgesic properties and can modulate visceral pain signaling, which is relevant to the chronic pelvic pain that characterizes endometriosis. Notably, VIP has been found at altered levels in the peritoneal fluid of endometriosis patients, suggesting a role in the disease's pathophysiology, though whether supplemental VIP would be therapeutic is unknown. Low-dose naltrexone (LDN) is the most clinically relevant option in this list, with a growing body of evidence for chronic pain and inflammatory conditions. LDN works by transiently blocking opioid receptors, which triggers upregulation of endogenous endorphin production and modulates microglial activation — a key driver of central pain sensitization. Several case series and small clinical studies have reported meaningful pain reduction in endometriosis patients using LDN at doses of 1.5-4.5mg daily. While large randomized controlled trials are still lacking, LDN has a favorable safety profile and is increasingly prescribed off-label for endometriosis-related pain. The honest assessment is that LDN has the most clinical traction for endometriosis among these options, BPC-157 and KPV have relevant anti-inflammatory mechanisms but no endometriosis-specific data, and VIP has interesting immunological relevance that remains entirely preclinical.